Genomic Epigenetic Proteomic Metabolomic and Immunologic Characterization of

Recruiting

99 years or below

All

40 participants needed

1 Location

Brief description of study

mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells surviving TACE or TARE.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: TBD
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 825782

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Genomic Epigenetic Proteomic Metabolomic and Immunologic Characterization of Metastatic Neuroendocrine Tumors Surviving Transarterial Embolotherapy

Brief description of study

Eligibility of study

Find a site

Interested in the study